Press Releases

Cynapsus Therapeutics Obtains Final Court Order and HSR Waiting Period Expires for Plan of Arrangement with Sunovion Pharmaceuticals

Oct 18, 2021

Cynapsus Therapeutics Securityholders Approve the Plan of Arrangement with Sunovion Pharmaceuticals

Oct 13, 2021

ISS Recommends Cynapsus Therapeutics Securityholders Vote for the Plan of Arrangement

Sep 28, 2021

Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics

Aug 31, 2021

Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease

Aug 29, 2021

Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson’s Disease Clinical Study Allowing for At-Home Titration

Aug 15, 2021

Cynapsus Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease

Aug 12, 2021

Cynapsus Therapeutics Reports Second Quarter 2016 Financial Results and Recent Developments

Aug 10, 2021

Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease

Jul 18, 2022

Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease

Jul 18, 2022

1
2
3
4
5
6
7
8
9
10
...15
Next »